Sucralfate NDC 69238-1656

NDC codes

FDA NDC Directory

Product NDC (as listed)69238-1656Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69238-1656Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69238-1656-1	69238165601	100 TABLET in 1 BOTTLE (69238-1656-1)Marketed from Apr 22, 2022
69238-1656-5	69238165605	500 TABLET in 1 BOTTLE (69238-1656-5)Marketed from May 23, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/1
Dosage form: Tablet
Route: Oral
Labeler: Amneal Pharmaceuticals NY LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215576
Marketing start: Apr 22, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 69238-1656_507ba68d-7593-4545-bbe1-dc9463c1a893SPL ID 507ba68d-7593-4545-bbe1-dc9463c1a893SPL set ID a4f722e7-2885-4f27-8358-9c662439600aRxCUI 314234UNII XX73205DH5UPC 0369238165616
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469238165601 followed by a unit qualifier and the quantity

Package 69238-1656-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 30, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate tablets are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215576

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215576
Product	Strength	Form · route	Labeler	Product NDC
Sucralfate	Sucralfate 1 g/1	TabletOral	AvKARE	42291-936
Sucralfate	Sucralfate 1 g/1	TabletOral	Amneal Pharmaceuticals NY LLC	60219-1656